<DOC>
	<DOCNO>NCT02734524</DOCNO>
	<brief_summary>The main purpose study explore combination autologous NK cell infusion chemotherapy increase therapeutic efficiency treatment non-small cell lung cancer compare chemotherapy alone .</brief_summary>
	<brief_title>A Clinical Research NK Cell Infusion Combined With Chemotherapy Treatment Non-small Cell Lung Cancer</brief_title>
	<detailed_description>Natural killer cell play important role anti-tumor process mediate innate immunity . However , past research show dissatisfactory clinical outcome clinicaltrials use autologous NK cell infusion alone . With expectation combination autologous NK cell infusion chemotherapy may increase therapeutic efficiency chemotherapy alone cancer treatment , investigator design conduct randomize controlled trial treatment non-small cell lung cancer .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>1 . Nonsmall cell lung cancer must diagnose pathology stag ⅢB Ⅳ 2009UICC TNM stag system operation exclude due medical reason patient 's . 2 . According Response Evaluation Criteria Solid Tumors ( RECIST ) , least one measurable evaluable nidus detect chest CT. 3 . ECOG score 01 . 4 . Gender limit , age 18 year 75 year . 5 . Patients expect survive 3 month physician time enrollment . 6 . Mental state evaluate normal . 7 . Adequate cardiac function ( LVEF≥40 % , test within one month ) without heart disease . 8 . Hepatic renal function normal , biochemical criterion must meet request : white blood cell count≥2.5×10^9/L，platelet count≥100×10^9/L，hemoglobin≥90g/L , serum bilirubin≤2 upper limit normal ( ULN ) , AST ALT≤2 ULN ( AST , ALT≤5ULN hepatic metastasis ) , Bun≤2 ULN , serum creatinine≤2 ULN . 9 . No serious illness ( e.g. , autoimmune disease , immunodeficiency , ect. ) . 10 . Ability give inform consent . 11 . No malignancy diagnose . 12 . Patients volunteer participate research . Subjects meet follow criterion eligible participation study : 1 . Frequent infection history recent infection uncontrolled . 2 . Patients concomitant genetic syndrome : patient Down syndrome , Fanconi anemia , Kostmann syndrome , Shwachman syndrome know bone marrow failure syndrome 3 . Concurrent use systemic steroid chronic use immunosuppressant medication . Recent current use inhale steroid exclusionary . For additional detail regard use steroid immunosuppressant medication . 4 . Pregnancy nursing female . 5 . HIV infection . 6 . Active hepatitis B active hepatitis C. 7 . Participation prior investigational study within 4 week prior enrollment longer required local regulation . Participation nontherapeutic research study allow . 8 . Class III/IV cardiovascular disability accord New York Heart Association Classification . 9 . Patients known history prior diagnosis serious immunologic , malignant inflammatory disease . 10 . Other situation think eligible participation research .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Natural killer cell</keyword>
	<keyword>NSCLC</keyword>
	<keyword>NCT</keyword>
	<keyword>Combined therapy</keyword>
</DOC>